Navigation Links
Improvement in Beta-Cell Function Observed After Three Years of BYETTA(R) Therapy: Data Presented at ADA 2010
Date:6/26/2010

ORLANDO, Fla., June 26, 2010 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced results from a study comparing the effect of long-term treatment with either BYETTA® (exenatide) injection or Lantus® (insulin glargine) on overall beta-cell function. (Beta cells are cells in the pancreas that produce insulin.) Three years of BYETTA therapy improved indices of beta-cell function assessed four weeks after discontinuing therapy. These findings were presented at the 70th Annual Scientific Sessions of the American Diabetes Association (ADA) in Orlando, Fla.

After three years of treatment, both therapies reduced A1C similarly (by 0.7 percentage points to 6.6 percent for BYETTA and by 0.5 percentage points to 6.9 percent for Lantus). A1C is a measure of average blood sugar over three months. In addition, BYETTA significantly reduced body weight compared to Lantus (17-pound difference between groups). After completion of three years of therapy, a four-week off-drug period followed to allow assessment of parameters of metabolic state including beta-cell function. Beta-cell function was assessed using a calculated disposition index (insulin secretion adjusted for insulin sensitivity). BYETTA increased insulin sensitivity by 39 percent and increased the disposition index, indicating an improvement in background beta-cell function. Lantus had no effect on insulin sensitivity or disposition index.

"Type 2 diabetes is a progressive disease in which insulin production typically decreases over time," said '/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Study Data Show INTUNIV™ (guanfacine) Extended Release Tablets Co-administered With Stimulants Provided ADHD Symptom Improvement in Children and Adolescents
2. Renhuang Pharmaceuticals Announces Continual Improvement in Days Sales Outstanding
3. Garnet BioTherapeutics Announces First Patient Treated in Trial of New Therapy for Improvement in Scar Appearance
4. PARI Pharmas Altera Delivers Gileads Cayston, Approved by the U.S. FDA for the Improvement of Respiratory Symptoms in Cystic Fibrosis Patients With Pseudomonas aeruginosa
5. Phase 2 Trial of LX4211 Demonstrates Significant and Rapid Improvements in Multiple Parameters in Type 2 Diabetic Patients
6. AstraZeneca Offers Online Enrollment and Additional Improvements to Patient Assistance Program
7. Solos Endoscopy, Inc. Makes Significant Design Improvement To Its MammoView(TM) Ductoscope
8. NQF Helps Ensure Health IT Captures Information to Drive Quality Improvement
9. New Data Show CIMZIA(R) (certolizumab pegol) Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohns Patients
10. 18 month Follow-up Data on Phase III Study of Pixantrone in Late Stage Relapsed or Refractory, Aggressive Non-Hodgkins Lymphoma Continues to Demonstrate Significant Improvement in Complete Remission and Progression Free Survival Over Standard Chemotherap
11. Two-Year Data Show Patients Receiving SIMPONI(TM) (golimumab) Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis and Ankylosing Spondylitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)...  The board of directors of VirtualScopics, Inc. (NASDAQ: ... trial imaging solutions, today announced that James Groff ... immediately.  Mr. Groff has held the role of acting ... in January 2006 as an accounting manager and was ... the board of VirtualScopics asked Jim to assume the ...
(Date:8/21/2014)... Aug. 21, 2014  SI-BONE, Inc. ( San ... pioneered the use of the iFuse Implant System, ® ... fusion of the sacroiliac (SI) joint, announced that Priority ... to its Lumbar Fusion Medical Policy No. 91590-R4 providing ... The policy states that the fusion procedure, which employs ...
(Date:8/20/2014)... , Aug. 20, 2014  The National ... the latest results achieved by the real-time, pseudoephedrine ... the National Precursor Log Exchange (NPLEx), automatically blocks ... track down meth offenders and make arrests. Data ... Kentucky blocked the sale of ...
Breaking Medicine Technology:VirtualScopics, Inc. Names James Groff Chief Financial Officer 2VirtualScopics, Inc. Names James Groff Chief Financial Officer 3VirtualScopics, Inc. Names James Groff Chief Financial Officer 4SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 2SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 3Kentucky's Stop-Sale System Achieves Significant Results In Battle Against Meth 2
... MISSISSAUGA, Ontario, March 11, 2011 Valeant Pharmaceuticals ... VRX) announced that effective March 10, 2011, the ... S.A. About Valeant Valeant Pharmaceuticals ... pharmaceutical company that develops, manufactures and markets a ...
... (Nasdaq: OPTR ) today announced 2010 fourth quarter ... (Logo:   http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO ) Optimer reported a ... of $11.9 million, or $0.31 per common share, as compared ... common share, for the same period in 2009.  Optimer reported ...
Cached Medicine Technology:Optimer Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 2Optimer Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 3Optimer Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 4Optimer Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 5Optimer Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 6Optimer Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 7Optimer Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results 8
(Date:8/21/2014)... 21, 2014 The results of a ... The Journal of the American Medical Association (JAMA) show ... and reduces unnecessary recalls. Memorial Healthcare System was one ... , “This study confirms what we already know – ... we want to find and, at the same time, ...
(Date:8/21/2014)... 2014 The report "Industrial Flue ... Control System (FGD, DeNOx, Particulate Control, Mercury Control) ... Chemical & Others) - Global Trends & Forecasts ... flue gas treatment systems & services market with ... in terms of value. The industrial flue gas ...
(Date:8/21/2014)... Lauren Collura, a mother of two from ... the Boardwalk” Facebook sweepstakes. Lauren, her husband, and two children ... house in Lavallette beginning this Saturday. , This is ... Last year, Horizon Blue Cross Blue Shield of New Jersey ... and decided to make it a new summer tradition. ...
(Date:8/21/2014)... American Addiction Centers, a leading national provider of inpatient ... alcohol addiction, has been named to the Inc. 500 ... company is ranked 7th on the “Top 20 Tennessee ... list in the “Nashville Metro Area” sub-category. With a ... (AAC) ascended to number 474 on the larger list ...
(Date:8/21/2014)... Aug. 21, 2014 (HealthDay News) -- Using two types ... the disease and may boost efforts to eradicate polio, ... 1,000 children in India found that giving the Salk ... been given the Sabin live-attenuated oral poliovirus vaccine (OPV) ... causes polio. The findings, reported in the Aug. ...
Breaking Medicine News(10 mins):Health News:Dr. Mary Hayes: Study Shows 3D Mammography Finds More Invasive Cancers While Reducing Unnecessary Recalls 2Health News:Industrial Flue Gas Treatment Systems Market Estimated to Worth $59, 546.7 Million by 2019 – Report by MarketsandMarkets 2Health News:Industrial Flue Gas Treatment Systems Market Estimated to Worth $59, 546.7 Million by 2019 – Report by MarketsandMarkets 3Health News:Industrial Flue Gas Treatment Systems Market Estimated to Worth $59, 546.7 Million by 2019 – Report by MarketsandMarkets 4Health News:American Addiction Centers Named to Inc. 500 List Recognition for Three-Year Sales Growth of 995% 2Health News:Two Polio Vaccines May Give Greater Protection Against Crippling Disease 2
... for the AACR 102nd Annual Meeting 2011 is Friday, Feb. ... for editors and reporters, and we cannot guarantee that housing ... meeting will feature the latest findings in laboratory, translation and ... the meeting, including: nicotine supplements and tumor ...
... that infection with human immunodeficiency virus (HIV) impaired ... more HIV infected patients dropping off the transplantation ... and recurrence-free survival was not impacted following liver ... of this single center studythe largest to dateare ...
... used by caterpillars that transform into large white butterflies, ... leaves to make them smell and taste unpleasant to ... of this defence reduces the caterpillars, growth rate and ... unclear why their defences affect them in this way, ...
... Reinberg HealthDay Reporter , MONDAY, Jan. 24 ... cognitive behavioral therapy may reduce the risk of heart ... researchers report. About 30 percent of heart attacks may ... poverty or emotional problems, such as depression and hostility, the ...
... have saved $77 million in 2006 if it ... cardiovascular drugs angiotensin receptor blockers without a negative ... published in CMAJ (Canadian Medical Association Journal) (pre-embargo ... costs in Canada increased by more than 200% ...
... Reporter , MONDAY, Jan. 24 (HealthDay News) -- Doctors ... pain report that they discovered the treatment consistently lowered ... introduces the possibility that deep brain stimulation -- ... brain -- might one day become a treatment for ...
Cached Medicine News:Health News:The American Association for Cancer Research hosts its 102nd Annual Meeting 2Health News:Patients infected with HIV have higher drop-out rate for liver transplantation 2Health News:Insects that deter predators produce fewer offspring 2Health News:Stress-Reduction Therapy May Help Heart Disease Patients 2Health News:Stress-Reduction Therapy May Help Heart Disease Patients 3Health News:Controlling the rising costs of cardiovascular care 2Health News:Deep Brain Stimulation Might Ease Tough-to-Treat Hypertension 2
Albarran double-horn bridge for use with sheaths from 20-25 Fr and designed for accurate articulation of flexible devices....
... and removal in the urinary tract. The nitinol ... shape following extreme torsion. The unique tipless design ... basket to open at the base of the ... reduces the likelihood of mucosal damage and perforation. ...
Bard Coude-Tip Latex Urethral Catheter, Two Eyes (Tiemann Model)...
Red Latex Bardex I.C. Foley 2-Way Catheter (Council Model)...
Medicine Products: